Literature DB >> 17204864

Spontaneous tumor lysis syndrome in acute myeloid leukemia: two cases and a review of the literature.

Brett Riccio1, Anthony Mato, Erin M Olson, Jeffrey S Berns, Selina Luger.   

Abstract

Spontaneous tumor lysis syndrome (TLS) is a constellation of electrolyte abnormalities and acute renal failure, which occurs in the setting of rapid cell turnover prior to the administration of cytotoxic chemotherapy. While spontaneous TLS is well described in patients with Burkitt's lymphoma, it is thought to occur less commonly in other hematologic malignancies. We present two cases of spontaneous TLS in patients with newly diagnosed acute myeloid leukemia (AML) followed by a review of the literature in this field.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17204864     DOI: 10.4161/cbt.5.12.3610

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  15 in total

Review 1.  Kidney diseases associated with haematological cancers.

Authors:  Anirban Ganguli; Deirdre Sawinski; Jeffrey S Berns
Journal:  Nat Rev Nephrol       Date:  2015-06-02       Impact factor: 28.314

Review 2.  Tumor lysis syndrome: new challenges and recent advances.

Authors:  F Perry Wilson; Jeffrey S Berns
Journal:  Adv Chronic Kidney Dis       Date:  2014-01       Impact factor: 3.620

3.  Spontaneous Tumor Lysis Syndrome in an Infant: A Case Report.

Authors:  Mamatha T Shenoy; Benedicta D'Souza; Lalesh Naik Akshatha; Vivian D'Souza; Madan Gopal Rajan
Journal:  Indian J Clin Biochem       Date:  2015-02-14

4.  Spontaneous tumor lysis syndrome in the setting of B-cell lymphoma.

Authors:  Mateusz Opyrchal; Travis Figanbaum; Amit Ghosh; Vincent Rajkumar; Sean Caples
Journal:  Case Rep Med       Date:  2010-03-10

5.  Tumor lysis syndrome and malignant melanoma.

Authors:  Meir Mouallem; Noa Zemer-Wassercug; Eitan Kugler; Nadav Sahar; Ronnie Shapira-Frommer; Ginette Schiby
Journal:  Med Oncol       Date:  2013-05-15       Impact factor: 3.064

6.  Spontaneous tumor lysis syndrome in a patient of chronic lymphocytic leukemia.

Authors:  Ajay Gogia; Vinod Raina; Nida Iqbal; Vijaya Murugan
Journal:  Indian J Med Paediatr Oncol       Date:  2014-01

Review 7.  Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies.

Authors:  Ali McBride; Peter Westervelt
Journal:  J Hematol Oncol       Date:  2012-12-13       Impact factor: 17.388

Review 8.  Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.

Authors:  Lisa Cammalleri; Mariano Malaguarnera
Journal:  Int J Med Sci       Date:  2007-03-02       Impact factor: 3.738

9.  Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).

Authors:  Andrea Pession; Fraia Melchionda; Claudia Castellini
Journal:  Biologics       Date:  2008-03

10.  Hyperphosphatemia during spontaneous tumor lysis syndrome culminate in severe hypophosphatemia at the time of blast crisis of Phneg CML to acute myelomoncytic leukemia.

Authors:  Ophira Salomon; Eli J Holtzman; Pazit Beckerman; Camila Avivi; Luba Trakhtenbrot; Abraham Kneller; Tali Tohami; Yeroham Kleinbaum; Sara Apter; Ninette Amariglio; Ehud Grossman; Ginette Schiby
Journal:  Exp Hematol Oncol       Date:  2012-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.